Expert disagreements, alternative perspectives, and minority opinions.
“Characterising obesity as a 'neurometabolic disease' treatable with individual pharmaceutical intervention medicalises what is primarily a symptom of a dysfunctional food environment. Widespread adoption of expensive long-term peptide therapy may distract from the structural changes — regulating ultra-processed foods, rebuilding food systems — that would address upstream drivers.”
Detail
A peptide protocol alone cannot fix a broken food environment. The drugs work at the individual level; the diagnosis at the population level may be incomplete. Read this critique as a reminder that the intervention lives on top of an environmental base, not as a replacement for it.
“Focusing on weight as the definitive health indicator is stigmatising and medically questionable. Metabolic health can be achieved at a range of body weights, and the drive to lower BMI through drug therapy may cause more psychological and physical harm — particularly through weight cycling — than the initial state of higher weight.”
Detail
The HAES framing contains a genuine point — metabolic biomarkers, cardiovascular fitness, and metabolic health can be meaningfully improved without weight loss, and repeated weight cycling has independent physiological costs. It also contains a contested claim — that all weight loss is harmful. The honest reading: weight loss in the context of metabolic disease is clinically indicated; weight loss as a cosmetic intervention in someone who is metabolically healthy at a higher weight is a different calculus.
“Excessive food intake is often a coping mechanism for trauma, stress, or deep-seated psychological issues that a 'biological dial' cannot fix. Suppressing appetite without addressing the underlying emotional cause risks 'symptom substitution' — where the patient turns to other addictive or compulsive behaviours to meet the same need the eating was meeting.”
Detail
The symptom-substitution concern is clinically real in some patients and absent in others. GLP-1 anhedonia reports intersect with this — 'food noise' reduction can expand into broader reward-pathway flattening. In patients with a trauma history or a known psychological component to eating behaviour, concurrent psychological support is not optional. In patients where the driver is more straightforwardly metabolic, the concern is smaller.
“Maintaining supraphysiological GLP-1 signalling over multi-decade timescales may drive receptor down-regulation and permanent shifts in the body's satiety set-point. Once the pharmacological drive is removed, the body may be less capable of maintaining weight homeostasis than it was before treatment — a drug-induced dependency the original trials were not designed to detect.”
Detail
Post-discontinuation weight regain is well-documented. Whether this reflects return-to-baseline biology (no set-point damage, body returning to its prior state) or pharmacologically-induced set-point shift (body worse off than pre-treatment) is not settled. Plan for long-term therapy rather than short courses, or structure supervised discontinuation protocols with adequate follow-up. The research to distinguish these hypotheses at multi-decade timescales does not yet exist.
“Beyond FDA-approved protocols, a large community of patient-led experimenters sources research-grade peptides directly and 'stacks' multi-class combinations (semaglutide + cagrilintide; retatrutide + cagrilintide; experimental fragments) without medical supervision. This community argues institutional medicine is slow, expensive, and over-cautious relative to the actual risk profile.”
Detail
This is the stance most directly responsible for the documented harm in this class — 10-fold overdoses, counterfeit-insulin poisoning, amphetamine adulteration. 'Patient-led experimentation' is a reasonable description of what some users are doing; 'a dominant source of preventable harm' is also accurate. The grey-market critique of institutional slowness contains a grain of truth; the execution on 'solve it with unverified chemicals' is a separate question and has a measurable body count. Read this view as information about what a subset of users actually do, not as a recommended approach.